Sagent Pharmaceuticals, Inc.

Portfolio focused on high-quality FDA approved products to treat patients in acute care hospitals, outpatient clinics and physician offices; pursuing 25+ new products over next two years Differentiated business model ensures supply chain resiliency through established manufacturing partner network Seasoned team with proven track record of launching critical medications includes Jeffrey Yordon, CEO Company to highlight expertise at CPhI Conference in Barcelona on October 24-26 SCHAUMBURG, Ill.--(BUSINESS WIRE)-- Avenacy, a specialty pharmaceutical company focused on developing, manufacturing, and delivering critical medications, today announced its launch. Supported by a vast global network of development and manufacturing partners, Avenacy is prepared to meet the needs of today’s dynamic drug supply chain while ensuring quality of care to patients. Through a rigorous and optimized selection process, Avenacy is building out a portfolio of high-quality FDA approved products capable of delivering sustainable growth while providing reliability, safety, and convenience for customers. Products will cover a range of critical medications used to treat patients in various medically-supervised settings, from acute care hospitals to outpatient clinics and physician offices. All products will feature Avenacy’s unique packaging and labeling designed to assist healthcare providers with accurate medication selection, thereby supporting a reduction in administration errors and improper dosing. Avenacy will also provide ready-to-use formulations of essential medications to help address dosing inaccuracies, enhance patient safety, and streamline efficiency – all with the ultimate goal of improving patient care. “At Avenacy, we are advancing a partnership-driven business model that will enable us to be cost-efficient and nimble to market by focusing on product investment while minimizing manufacturing costs. With nearly 20 development and manufacturing partners already in place across five key geographies, we are well-equipped to begin fulfilling the needs of healthcare systems and providers,” said Jeff Yordon, Co-Founder and CEO of Avenacy. “Our team brings a long-standing legacy in specialty pharmaceuticals and a reputation for prioritizing quality, safety, and reliability. Everything we do, from product selection to partner assessment and supply chain management, will be underpinned by an unwavering commitment to applying the highest industry standards, championing patient safety, and ensuring a dependable drug supply.” The Avenacy team and its founders Jeffrey Yordon and Kam Phulwani have a proven track record in building successful specialty pharmaceutical companies. The Company is led by Jeffrey Yordon, who previously served as COO of Athenex, Inc. and President of Athenex Pharmaceutical Division, a successful specialty injectable business that launched over 50 products and delivered nearly 40% CAGR revenue growth from 2017-2022. Before joining Athenex, Mr. Yordon founded and led Sagent Pharmaceuticals, a global specialty pharmaceutical company, which was ultimately acquired by Nichi-Iko Pharmaceuticals Company in 2016. Drawing on prior experience and success in specialty pharmaceuticals, Kam Phulwani made a significant investment to fund Avenacy and its expanding pipeline of products for the U.S. market. The management team brings over 245 collective years of industry experience spanning pharmaceutical development, quality, manufacturing, and sales. Avenacy is well-positioned to address key gaps in the U.S. drug supply landscape. The Company employs a multifaceted strategy incorporating rigorous quality standards, a global partnership model, and deep relationships across the drug development and manufacturing ecosystem, to ensure a dependable and resilient drug supply. Additionally, the industry has been increasingly plagued by shortage issues, with the number of active drug shortages peaking at 301 in the first quarter of 2023. As an essential medicines provider, Avenacy is committed to acquiring products historically facing lower supply, and has an open dialogue in place with the U.S. Food and Drug Administration (FDA) about products at risk for shortages. Avenacy will be showcasing its differentiated business model, diverse partner network, and experienced leadership team at this year’s CPhI 2023 Conference, taking place in Barcelona from October 24-26. During this time, the Company will be hosting meetings with potential partners, customers, and investors, as it continues to expand its global presence. About Avenacy Avenacy is a U.S.-based specialty pharmaceutical company focused on developing, manufacturing, and delivering critical medications used to treat patients in various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices. Through a rigorous and optimized selection process, the Company is building out a pipeline of high-quality FDA approved products in order to ensure a resilient portfolio that can meet the needs of today’s dynamic drug supply chain. With an experienced team, commitment to quality and reliability, and product offerings intended to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential medications. Avenacy was launched in 2023 and is headquartered in Schaumburg, IL. For more information, please visit . View source version on businesswire.com: Contacts FTI Consulting Avenacy@fticonsulting.com Source: Avenacy View this news release online at:

LINCOLNSHIRE, Ill.--( BUSINESS WIRE )--Nexus Pharmaceuticals LLC, a privately-owned U.S.-based healthcare company has announced the appointment of Edgar Lee and Mike Warmuth to the company’s board of directors, effective immediately. The current board is composed of nine members and is led by founder and Chair of the Board of Directors, Mariam S. Darsot. The appointments come as Nexus works to expand its offerings to include new products as well as Nexus Pharma Services . “We look forward to the guidance of our new members, who will help Nexus continue to grow and meet the demands of a changing healthcare landscape,” said Ms. Darsot. “They bring with them a wealth of experience and a deep understanding of our mission, which will be invaluable as we continue to innovate and expand our services.” Mr. Lee is the Founder and Managing Member of Sagent Group and brings over twenty years of experience investing in and advising companies in the life sciences and technology, media, and telecommunications industries. Prior to the founding of Sagent Group, he served as the founder and portfolio manager of Oaktree’s $6 billion Strategic Credit strategy as well as serving as CEO and CIO of the organization’s three business development companies. Mr. Lee also brings experience from his work in TMT investment banking at UBS in Los Angeles, fixed income at Lehman Brothers, management consulting at Katzenbach Partners (Booz & Co.) and economic research at the Urban Institute. He holds a B.A. degree in economics from Swarthmore College and a master’s degree from Harvard University. Mr. Warmuth was most recently an Operating Partner at EW Healthcare Partners from 2018 to 2022. Prior to EW Healthcare Partners, Mr. Warmuth was at Abbott Laboratories, where he led the Established Pharmaceuticals division which soon became one of the top ten largest generics companies across the globe and covered several therapeutic areas including gastroenterology, women’s health, cardiovascular, and metabolic disorders. His work at Abbott reflects a strong track record of success in driving operational excellence and growth through mergers and acquisitions. He holds a B.A. degree in Business Administration from the University of Wisconsin-Whitewater and a master’s degree from Northwestern University. About Nexus Pharmaceuticals LLC Nexus Pharmaceuticals LLC, a US-based healthcare company and certified diverse supplier, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor-intensive, and more streamlined in practice. Nexus ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment options when and where they’re needed most. For more information about Nexus Pharmaceuticals and its state-of-the-art Wisconsin manufacturing facility, visit https://www.nexuspharma.net/project-tomorrow/ .

Allan Oberman appointed as CEO to transform Apotex into a Canadian-based global health company. TORONTO, April 3, 2023 /PRNewswire/ - Apotex Pharmaceutical Holdings Inc. ("Apotex" or the "Company") today announced that its acquisition by an affiliate of funds advised by SK Capital Partners, LP ("SK Capital") has closed. The Company also announces that experienced pharmaceutical executive Allan Oberman has been appointed President and CEO and member of the Board of Apotex. Allan brings four decades of experience in corporate leadership to Apotex, including 20 years in the pharmaceutical industry. Most recently, he served as CEO of Concordia International Corp. and CEO of Sagent Pharmaceuticals Inc. Prior to these positions, he served as President and CEO of Teva Canada (formerly Novopharm Limited), COO of Teva International Group, President of Teva EMIA and President and CEO of Teva Americas Generics. Mr. Oberman has almost three decades of corporate governance experience, having served on numerous boards, including as Chairman of the Canadian Generic Pharmaceutical Association, and Vice-Chairman of the U.S. Association for Accessible Medicines. He has an MBA from the Schulich School of Business, York University, and a BA from Western University. "As a competitor to Apotex for many years, I am very familiar with the company and have admired its people, long-term track record of innovation and commitment to making medicines affordable to patients in Canada and worldwide," stated Allan Oberman, President and CEO of Apotex. "I'm excited to join the team and build on that legacy." "We welcome Allan to the Apotex team. His experience leading major Canadian and international pharmaceutical companies and delivering enhanced shareholder value will benefit Apotex as we grow into a Canadian-based global health company," said Aaron Davenport, Chairman of the Board of Apotex and Managing Director at SK Capital. "SK Capital looks forward to working with Apotex as it moves into its next phase of growth, leveraging its iconic brand, broad product portfolio, international presence and skilled team." Jeff Watson, Apotex's CEO since 2018, will join the Apotex Board of Directors. "We thank Jeff for his leadership and welcome him to the Board, where we will continue to benefit from his stewardship and counsel," added Mr. Davenport. About SK Capital SK Capital is a private investment firm with a disciplined focus on sectors that create the building blocks of modern life and a more sustainable future, including specialty materials, ingredients, and life sciences. The firm seeks to build strong and growing businesses that create substantial long-term economic value. SK Capital aims to utilize its industry, operating, and investment experience to identify opportunities to transform businesses into higher-performing organizations with improved strategic positioning, growth, and profitability, as well as lower operating risk. SK Capital's portfolio of businesses generates revenues of approximately USD $16 billion annually, employs more than 20,000 people globally and operates 203 plants in 32 countries. The firm currently has approximately USD $7.2 billion of assets under management. For more information, please visit skcapitalpartners.com. About Apotex Apotex is a proudly Canadian, global pharmaceutical company that produces high-quality, affordable medicines for patients around the world. Apotex employs nearly 8,000 people worldwide in manufacturing, R&D, and commercial operations. Apotex exports to more than 100 countries and territories and operates in more than 45 countries, with a significant presence in Canada, the United States, Mexico, and India. For more information, visit . SOURCE Apotex Inc.